| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5792795 | ASTRAZENECA | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May, 2020
(3 years ago) | |
| US5948818 | ASTRAZENECA | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May, 2020
(3 years ago) | |
| US9132112 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US8383678 | ASTRAZENECA | Type a gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US9012501 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US7960370 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Dec, 2026
(2 years from now) | |
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
Epanova is owned by Astrazeneca.
Epanova contains Omega-3-Carboxylic Acids.
Epanova has a total of 9 drug patents out of which 2 drug patents have expired.
Expired drug patents of Epanova are:
- US5792795
- US5948818
Epanova was authorised for market use on 05 May, 2014.
Epanova is available in capsule;oral dosage forms.
Epanova can be used as treatment of hypertriglyceridemia, treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet.
Drug patent challenges can be filed against Epanova from 05 May, 2018.
The generics of Epanova are possible to be released after 04 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet
Dosage: CAPSULE;ORAL
EPANOVA family patents
